SCA
CRL icon

Sandy Cove Advisors’s Charles River Laboratories CRL Stock Holding History

Sandy Cove Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,538
Closed -$417K – 115
2024
Q1 		$417K Hold
1,538
– – 0.19% 76
2023
Q4 		$364K Buy
1,538
+38
+3% +$7.47K 0.19% 81
2023
Q3 		$294K Buy
+1,500
New +$308K 0.17% 92

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Sandy Cove Advisors's CRL Position: Q2 2024 in Review

Sandy Cove Advisors sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 1,538 shares — an estimated $417K sold.

Sandy Cove Advisors first reported a position in CRL in Q3 2023 and held it in 3 quarters. The position peaked at $417K in Q1 2024. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Sandy Cove Advisors reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Sandy Cove Advisors sold 1,538 Charles River Laboratories shares in Q2 2024, an estimated $417K.
  • Sandy Cove Advisors first reported a position in Charles River Laboratories in Q3 2023 and held it in 3 quarters.
  • Sandy Cove Advisors's Charles River Laboratories position peaked at $417K in Q1 2024.
  • 665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Sandy Cove Advisors's 13F filing for Q2 2024, filed 23 Jul 2024.